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Introduction
In 2005, there were 40 597 deaths from ischaemic heart disease among the 62.4 million inhabitants in France, i.e. 7.7% of all deaths and one of the lowest rates in Europe [1] . The three French registers of acute coronary syndromes, obtained from the Multinational Monitoring of trends and determinants in Cardiovascular disease (MONICA) Project, observed an overall reduction in mortality between 1992 and 2002, particularly hospital fatality, but not in the incidence of coronary disease. This improvement can be explained partly by the increase and improvement in recommended invasive and non-invasive treatments [2, 3] .
In 2007, the French National Authority for Health (HAS) published guidelines for coronary disease management. As in many international recommendations on secondary prevention for patients with a myocardial infarction (MI), recommended medications include a combination of betablockers, aspirin and/or clopidogrel, statins and angiotensin-converting enzyme inhibitors (ACE-I), which may be replaced by an angiotensin-receptor-blocker (ARB) [4] .
These recommendations are based on the results of studies that observed decreased rates of cardiovascular death and serious cardiac events, as well as an advantageous cost-effectiveness ratio for each class of medications and their combination [5] . 'Real-world' studies in North America and Europe have observed a temporal increase in the use of secondary prevention therapy, although several characteristics were associated with a lower use of recommended medications (e.g., certain geographical regions, older age, female sex, presence of comorbid conditions or associated treatments, lower level of social protection, management at non-university hospitals, lack of followup by a cardiologist, or coronary artery bypass surgery) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . These studies were conducted on the basis of hospital data or of registers with populations of various sizes, but rarely nationwide. In France, a register of approximately 1700 patients recruited by a representative group of cardiologists reported a prescription level of 46.2% upon hospital discharge in 2006 for the selected combination of treatments, without taking into account ARBs [25] .
The objective of this study was to assess the level of use of medications recommended for secondary prevention, and of their combination, after hospitalization for MI in France, as well as the factors correlated with their use.
Methods
In France, the general health insurance scheme covers 70% of the population, i.e. 48 million people in 2006. Its information system (SNIIRAM) contains individualized, anonymous and exhaustive data on all health spending reimbursements. Other information is also recorded, such as the existence of universal healthcare coverage for low earners (CMUC) or for people suffering from one of 30 long-term disorders (LTDs) that entitle patients to full reimbursement. This information was linked to the French hospital discharge database, which is used for hospital payment and provides medical information for all patients discharged from both private and public hospitals.
Study population
All hospitalizations from January to June 2006 with a diagnosis-related group of MI (05K05 V, 05K05W, 05M02E, 05M03Z, 05M04 V, 05M04W and 24Z09E) were selected from the programme de médicalisation des sytèmes d'information (PMSI) data on short-term hospital stays. We selected patients who were covered by the general scheme and the first hospital admission for MI was selected as the index hospital admission. They were then linked, using a common, anonymous patient number, to the corresponding records in the reimbursement database. Contact with patients who received no treatment reimbursement four to six months after the index hospital admission was considered lost and were excluded. Possible reasons for lost contact include death after hospital admission, relocation abroad, change in social security number (e.g., widowed women) and treatment in a follow-up and rehabilitative care establishment after hospital discharge.
Variables studied
For each index hospital admission, the following were selected: diagnosis-related group, coronary stent implant procedure (coded according to the classification of medical procedures used in France: DDAF003, DDAF004, DDAF006-DDAF009), sex, age, length of stay and, for healthcare establishments, type of hospital and activity volume (number of admissions with a discharge diagnosis of MI in each establishment during 2006).
Consumption of a major class of medications (antihypertensive, antiplatelet, antidiabetic, anti-inflammatory and lipid-lowering drugs, oral anticoagulants, cardiotonic glycosides, class III antiarrhythmic agents, nitrates, vasodilators) was considered to be 'regular' after at least three medication deliveries per patient per six-month period (before and after the index hospital admission). No limit was set for heparins.
Cardiovascular morbidity (coronary artery disease: acute myocardial infarction, angina pectoris, coronary atherosclerosis; coronary artery bypass surgery; stent implantation procedures) was identified using specific diagnosis-related groups notified during hospital stays, six months before and after the index hospital admission. Hospitalizations for non-cardiovascular reasons (other diagnosis-related groups) were grouped into hospital stays 'other than cardiology'. Comorbid conditions were defined in several ways: patients with Alzheimer's disease, Parkinson's disease or depression were identified through reimbursements of specific treatments issued at least three times over the six months before the index hospital admission. For kidney failure, LTD patients with 'chronic kidney failure' and/or treated with dialysis were selected. Obstructive respiratory diseases were characterized by the reimbursement of indicator medications at least twice over the previous six months. Diabetic patients were identified by the specific LTD and/or three reimbursements of specific treatments over the six months before or after hospitalization. For malignant tumours, the following indicators were used: radiotherapy and chemotherapy sessions or hospital admission with a main diagnosis of cancer, or specific cancer LTD declared within the past two years. For psychiatric disorders and chronic liver disease, only the specific LTD was used. Appointments with a private cardiologist over the six months before and following the index hospital admission were recorded when there was at least one reimbursement for each of these periods. To study the impact of full reimbursement of medications, the specific LTDs for cardiovascular disease were also recorded.
Statistical analysis
Univariate and bivariate analyses were conducted to describe the patients included and to compare the rates medication use according to their baseline characteristics and treatments used before and after the index hospital admission (Kruskal-Wallis tests for continuous variables and the chi 2 test for discrete variables). For each recommended class of medication and for their combined use, the crude odds ratios (OR) with their 95% confidence intervals (CIs) were calculated. Multivariable logistic regression analysis was used to test independent correlates of the use of individual and combined secondary prevention medications. Combination therapy was adjusted for sex and age. An overall adjustment was used for each individual class of medications. A p value less than 0.05 was considered to be statistically significant. The data were analysed using SAS software (SAS version 9.1.3, SAS Inc, Cary, NC).
Results

Population and treatment
In the first half of 2006, 24 075 hospital stays had an MI diagnosis-related group. The anonymous patient number was missing for 1707 (7.1%) of these and, of the 22 374 remaining, only 14 788 (66.1%) hospital admissions concerned 14,007 patients covered by the general health insurance scheme. As specified in the methods section, patients who died in hospital (n = 1354, 9.7%) were excluded, as well as the other 982 (7.0%) lost contacts after the hospital stay. The study focused on the remaining 11 671 patients, whose baseline characteristics and treatments are described in Table 1 .
Of those, 69.7% of patients were men (mean age 61.4 ± 13.6 years) and 30.3% women (mean age 72.6 ± 14.0 years). Men and younger patients were more often hospitalized in university hospitals or private clinics, and in centres with a high MI activity volume. During the index hospitalization, 57.2% of patients had a percutaneous coronary intervention (PCI) with implantation of at least one stent.
During the six months prior to hospital admission for MI, 14.4% of patients had consulted a private cardiologist, 10.9% had been hospitalized for cardiovascular causes including 2.8% with a stent implantation. In the six months following the index hospitalization, 46.3% consulted a private cardiologist and 45.3% had a further hospital record for cardiovascular causes, 15.6% with a stent implantation and 3.4% for coronary artery bypass surgery. The most common comorbidities were diabetes (21.4%), illnesses treated with anti-inflammatory medications (13.8%), depression (8.9%), obstructive pulmonary disease (8.4%) and cancer (4.7%). The proportion of patients with a registered LTD for coronary disease increased from 11.4 to 63.3% after hospitalization, while the proportion of other cardiovascular LTDs was more stable (12.7 to 18.3%). At six months, 11.0% of the patients had no administrative record of any LTD. Table 2 reports the use of the four classes of medications according to the patients' baseline characteristics. Before index hospitalization for MI, the use of each of the four groups was around 25%, except ACE-I/ARB (34%), with 6% taking a combination of these four classes. After hospitalization, reimbursed prescription rates rose to 82.4% for betablockers, 92.0% for antiplatelet agents, 85.4% for statins and 79.5% for ACE-I/ARB; 62.1% of patients were on a combination of these treatments. Regarding antiplatelet agents, 79.9% of patients received clopidogrel, 84% aspirin and 72% both.
Medications reimbursed
Correlates of use of recommended medications
Factors associated with the use of recommended medications are reported in Tables 3 and 4 . Men were more likely than women to take antiplatelet agents or combination treatment. Age had a significant effect, especially on the consumption of statins and ACE-I/ARBs, with fewer younger or older patients using these medications. Consumption of betablockers was significantly lower in patients more than or equal to 75 years and that of antiplatelet agents was lower in those more than or equal to 85 years. Combined therapy was much less frequently used in patients aged more than or equal to 75.
Consumption of betablockers, statins, ACE-I/ARBs and combination therapy was more frequent after admission to a university hospital. Admission to high MI volume hospitals was positively correlated with the use of statins, ACE-I/ARBs and combined treatment. Consumption of each of the four classes and their combination was higher when the patients had had at least one visit to a private cardiologist.
Stent implantation, during and after the index hospital admission, was positively and significantly associated with posthospitalization use of each of the classes and of their combination. Readmission to hospital for coronary disease increased consumption of combined therapy.
Overall, comorbidities (cancer, kidney failure, Parkinson's disease and Alzheimer's disease, etc.) had a negative influence on the use of recommended medications. Diabetes, however, was associated with a higher consumption of each class and of their combination.
A positive correlation was observed between the use of diuretics and that of ACE-I/ARBs or betablockers. Use of calcium-channel blockers was negatively associated with combined therapy, betablockers and ACE-I/ARBs, and was positively associated with antiplatelet agents and statins. Several other medications were negatively linked to class III antiarrhythmics and betablockers, fibrates and statins, oral anticoagulants and antiplatelet agents.
Discussion
This study, which combined hospitalization and reimbursement data for 11,671 patients admitted for MI in the first half of 2006, is the first to use such a methodology in this medical context in France. The data show that 62% of patients take the recommended quadruple therapy over the six months following hospitalization for an MI.
Comparisons with international and French data
Compared with international data, the level of use of combined therapy and of each class of medications appears high in France, especially for statins and antiplatelet agents [6] [7] [8] [9] [10] [11] [12] [22] [23] [24] . Comparisons between studies are limited by the variation of inclusion criteria, the techniques used to measure consumption of medications, patients case-mix, the year of study, and developments in professional practice recommendations and health coverage systems. In industrialized countries, a regular increase in the prescription of recommended medications has been observed since the end of the 1990s [6] [7] [8] [9] [10] . The current data represent a major improvement compared with data reported in France in 2000 from a register of 2119 patients, which recorded 52% use of combined betablockers, antiplatelet agents and statins, and a 27% prescription of quadruple combination therapy at hospital discharge [26] . At the end of 2004, in a register of 2443 patients followed-up by cardiologists after an acute coronary syndrome, 94.8% were taking aspirin, 90% statins, 85% thienopyridines, 79% betablockers, 47.7% ACE-I and 13.3% ARBs/sartan upon discharge from hospital for MI [27] . In another survey of 1700 patients, carried out in 2006, the proportion receiving quadruple therapy (excluding ARBs) was 46% [25] . These proportions may have been overestimated, as they were observed only for patients who consulted a cardiologist.
Correlates of use of recommended medications
Use of combination therapy should be limited mainly by absolute, and possibly relative, contraindications, or by intolerance to the medications. In theory, more than 95% of patients may be treated by statins, as true contraindications are rare. The same applies for ACE-I/ARBs, whereas contraindications are more common for betablockers. These were taken by 82% of patients, but higher levels at 90% have been reported in selected centres, such as was the case in the Global Registry of Acute Coronary Events (GRACE) [9] . Health coverage policies are likely to have an impact on medication consumption. The positive effect of financial reimbursement on prevention or care consumption has already been widely documented. In this regard, it is encouraging to note that patients receiving total reimbursement for treatment expenses (CMUC), have similar levels of use of recommended medications, in spite of their lower socioeconomic status.
The lower prescription of secondary prevention treatments in women is a concern. In this study, however, the lower rates observed in women disappeared after multivariable adjustment for all classes except antiplatelet agents. A low prescription of clopidogrel in women has already been reported [28, 29] . A lower frequency of stent or bypass use in women has also been reported, and is partly explained by their older age and by the particular anatomy of the coronary arteries in women [29] .
Older age is known to be a negative and independent factor against the use of prevention treatments [11] [12] [13] [14] [15] [16] [17] . In our study, the reduction in combined secondary prevention therapy over the age of 75 is due to the reduction in the use of statins and, to a lesser extent, betablockers and aspirin. The negative effect of age remained after adjustment. Although older age is associated with an increase in the frequency of cardiovascular comorbidities and possible interactions, which may contraindicate the prescription of secondary prevention medications, it is unlikely that these factors alone account for the drop in the use of secondary prevention medications in elderly patients. Although very few randomized trials have specifically been devoted to elderly populations, and the proportion of elderly patients in the trials is usually extremely low, there is no evidence that the efficacy of these medications in older patients is less. Indeed, a positive effect of betablockers and statins in patients aged 75 years and over has been observed in terms of both survival and cost-effectiveness [30] [31] [32] .
A paradoxical effect has been described for statins: their rate of prescription decreases as the patient's risk level increases [33] . This may be because prescribers think that these patients have a substantial risk of dying before the preventive measures have had time to take effect. Such a bias has been reported for the use of statins in Alzheimer's disease and Parkinson's disease or for psychiatric disorders [12, 14] . There is no question, however, that prescribing secondary prevention medications in patients with severe comorbidities may represent a true ethical issue for prescribers, which is beyond the scope of the present study to address. At the other end of the spectrum, the lower use of secondary prevention therapy in the very young (< 45 years) comes as a surprise and is of interest. Compared with patients aged 45 to 54 years, those less than 45 have significantly less chance of receiving the full combination of recommended medications; prescription is lower for all four classes of medications. One possible explanation could be that very young patients do not perceive the importance of taking several preventive medications on a regular basis. This will certainly need further investigation. Diabetic patients are at higher risk of an ischaemic event after an acute MI. In our study, and in contrast with other reports [19] , they had a higher level of use of combined therapy and of each class independently; while the difference, compared with non-diabetic patients, did not reach statistical significance before adjustment, it became highly relevant after full adjustment (OR 1.5). This may be the result of the emphasis that has been placed recently on the specificities and need for optimal care of the diabetic population with coronary artery disease. The recent Euro Heart Survey programme confirms the benefits of the use of recommended therapy in diabetic patients [20] .
The negative association between concomitant diseases and use of secondary prevention medications is hardly surprising. The reasons for the under prescription range from possible contraindications (asthma and betablocking agents) to reluctance vis-à-vis the prescription of additional medications in patients already receiving a number of non-cardiovascular drugs. In contrast, secondary prevention medications are used more often in patients who undergo myocardial revascularization by coronary angioplasty or coronary artery bypass surgery. The positive impact of coronary angioplasty had been noted previously [34] ; data on the influence of coronary bypass surgery are contradictory, as combined secondary prevention therapy has previously been found to be lower in patients who have undergone bypass surgery [27] .
Finally, the positive association between visits to a cardiologist and the prescription of recommended medications is encouraging, and follows the process of implementing scientific knowledge in the medical community: guidelines are usually written by cardiology experts and are applied initially in academic institutions. The second step is their dissemination within the community of cardiology specialists, while the education of general practitioners and the patients themselves comes as the final steps. Conversely, patients with multiple comorbidities are more likely to be hospitalized in non-specialized centres, and comorbidities may therefore constitute confounding factors [22] .
Strengths and limitations
The strength and originality of this study are that it has cross-linked several medicoadministrative databases, thereby providing comprehensive hospitalization and medical consumption data. Because the general health insurance scheme covers 70% of the French population, our data are likely to be fairly representative of the level of care in France in 2006, though we cannot exclude that populations covered by other health insurance systems might have been treated differently. Access to reimbursement databases allowed us to use data on medications for concomitant, non-cardiovascular diseases as adjustment variables. The reimbursement database is comprehensive for all medications purchased and reimbursed and, in contrast with telephone or mail surveys, there are no non-responders. It does not take into account self-medication, rare in this context, nor the fact that some patients might buy the medications and not actually use (swallow) them; actual use of the medications, however, is certainly more likely when the medications have been purchased repeatedly than when drug usage is accounted for on the sole basis of medical prescriptions by the doctors or self-declaration by the patients. Assessment of medication consumption (mainly three reimbursements over six months) was based on the definitions used in pharmacovigilance and other studies, and is an approximation of actual drug usage. Finally, the medicoadministrative nature of the databases does not permit adjustment for certain specific clinical factors, such as those specifying the extent or clinical severity of the disease. This is not a problem with regard to the description of the use of medications, but limits the capacity to determine correlates of medication underuse. In medicoadministrative databases, diagnosis and comorbidities can be misclassified. Nevertheless, hospital mortality of coronary heart disease is generally estimated at 10%, as was found in our study. For comorbidities, diagnosis was strengthened by other data on specific medication reimbursement of full coverage for a long-term chronic disease.
Conclusions
The use of secondary prevention medications, including the recommended quadruple therapy, in the months following an acute MI appears rather satisfactory and has improved in recent years. Under utilization of secondary prevention therapy, however, remains a concern in several subsets of patients, such as the very elderly or the younger age groups, as it is for patients taken care of in less specialized centres. For these specific populations in particular, a continuous benchmarking process, such as has been implemented in England and Wales with the MINAP project [10] , would most probably contribute to improved patient care. Finally, these data appear encouraging with regard to the French health insurance system, which provides a uniform quality of care, independently of the patients' socioeconomic status.
